Overview

* Arcutis Q2 2025 net product revenue rises 164% yr/yr to $81.5 mln

* Company reports net loss of $15.9 mln, an improvement from prior year

* FDA approves ZORYVE foam for scalp and body psoriasis, boosting sales

Outlook

* Company anticipates Q4 approval for ZORYVE cream 0.05% in children

* Company focused on expanding ZORYVE's approved uses

* Arcutis advancing pipeline with ARQ-234 for atopic dermatitis

Result Drivers

* STRONG DEMAND - Revenue growth driven by increased demand for ZORYVE foam and cream, particularly following FDA approval for new indications

* PRESCRIPTION GROWTH - Over 439,000 prescriptions filled for ZORYVE cream 0.3% and 405,000 for ZORYVE foam since launch, reflecting high patient and physician satisfaction

* PIPELINE ADVANCEMENT - Continued advancement of ZORYVE and ARQ-234 pipeline, with new studies and regulatory submissions underway

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $81.50

Product mln

Revenue

Q2 Net -$15.89

Income mln

Q2 Basic -$0.13

EPS

Q2 $96.12

Operatin mln

g

Expenses

Q2 -$14.61

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Arcutis Biotherapeutics Inc ( ARQT ) is $20.00, about 23.4% above its August 5 closing price of $15.33

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)